Published in Health Business Week, March 26th, 2004
Sales for the year ended December 31, 2003, were $203.7 million, an increase of 15% over the $177.6 million reported during the same period in 2002. The incremental impact of foreign currency on sales for 2003 was a positive $7.1 million.
Net income for the year ended December 31, 2003, was $24.7 million, or $1.68 per diluted share, which included $4.9 million in litigation and after-tax settlement costs, a decrease of 5% from the net income of $25.9 million, or $1.76 per diluted share, for the same period in 2002.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.